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Abstract: Acute viral bronchiolitis represents the most common lower respiratory tract infection in infants and young 
children and is associated with substantial morbidity and mortality. Respiratory syncytial virus is the most frequently 
identified virus, but many other viruses may also cause acute bronchiolitis. There is no common definition of acute viral 
bronchiolitis used internationally, and this may explain part of the confusion in the literature. Most children with bron-
chiolitis have a self limiting mild disease and can be safely managed at home with careful attention to feeding and respira-
tory status. Criteria for referral and admission vary between hospitals as do clinical practice in the management of acute 
viral bronchiolitis, and there is confusion and lack of evidence over the best treatment for this condition. Supportive care, 
including administration of oxygen and fluids, is the cornerstone of current treatment. The majority of infants and children 
with bronchiolitis do not require specific measures. Bronchodilators should not be routinely used in the management of 
acute viral bronchiolitis, but may be effective in some patients. Most of the commonly used management modalities have 
not been shown to have a clear beneficial effect on the course of the disease. For example, inhaled and systemic corticos-
teroids, leukotriene receptor antagonists, immunoglobulins and monoclonal antibodies, antibiotics, antiviral therapy, and 
chest physiotherapy should not be used routinely in the management of bronchiolitis. The potential effect of hypertonic 
saline on the course of the acute disease is promising, but further studies are required. In critically ill children with  
bronchiolitis, today there is little justification for the use of surfactant and heliox. Nasal continuous positive airway   
pressure may be beneficial in children with severe bronchiolitis but a large trial is needed to determine its value. Finally, 
very little is known on the effect of the various interventions on the development of post-bronchiolitic wheeze. 
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INTRODUCTION 
  Clinical definitions of acute viral bronchiolitis vary   
between countries. While in many countries including the 
USA wheezing is fundamental for the diagnosis, in the U.K., 
Australia and New Zealand wheezing is not an obligatory 
diagnostic criterion [1, 2]. These differences in definition 
may account for part of the variability in study results; 
clearly, uniformity is needed to allow a comparison between 
studies performed in different parts of the world [3]. 
  Acute viral bronchiolitis is the most common lower res-
piratory tract infection in infants and young children. Al-
though only 2-3% of all children with bronchiolitis need 
hospitalisation, the disease is the leading cause of infant hos-
pitalisation in the USA and has been associated with sub-
stantial morbidity in both inpatient and outpatient settings [4-
7]. Respiratory syncytial virus (RSV) is the most frequently 
identified virus, but many respiratory viruses such as parain-
fluenza virus, influenza virus, rhinovirus and human metap-
neumovirus have been associated with acute viral bronchioli-
tis; further, young children with bronchiolitis often are in-
fected with more than one virus, most commonly with RSV 
and either human metapneumovirus or rhinovirus [5, 7, 8].  
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While a relation between acute viral bronchiolitis and subse-
quent recurrent wheeze (“post-bronchiolitic wheeze”) in later 
life has consistently been shown in clinical studies, there is 
no clear explanation for this association [5]. 
TREATMENT 
  Most children with acute viral bronchiolitis have a self 
limiting mild disease and can be safely managed at home 
with careful attention to feeding and respiratory status. Man-
agement mainly consists of good supportive care, and most 
infants do not require specific measures. Criteria for referral 
and admission may vary between hospitals. Generally, the 
decision to admit an infant with bronchiolitis to the hospital 
is based on the age of the patient, the phase of illness, the 
presence of risk factors, the severity of respiratory distress, 
the ability to take oral fluids, and social and local circum-
stances [8]. Clinical practice in the acute management of 
bronchiolitis varies widely even between centres in one 
country, and there is much controversy, confusion, and lack 
of evidence over the best treatment for this common, life-
threatening condition [5]. 
Oxygen Supplementation 
  Treatment of hospitalised infants very often includes 
oxygen supplementation to maintain haemoglobin saturation 
 92%. There is, however, no evidence on which to base 
haemoglobin saturation limits for admission, during admis-
sion or for discharge from the emergency department or hos-160    The Open Microbiology Journal, 2011, Volume 5  Ernst Eber 
pital. While the effect of supplemental oxygen on recovery 
from bronchiolitis is not known, oxygen supplementation is 
the prime determinant of the length of hospitalisation for 
infants with acute viral bronchiolitis [9]. Thus, the use of 
pulse oximetry has likely contributed to longer hospitalisa-
tions and greater use of health care resources [7]. In the most 
recent clinical practice guideline of the American Academy 
of Pediatrics (AAP) [1] the following options (options define 
courses that may be taken when either the quality of   
evidence is suspect or carefully performed studies have 
shown little clear advantage to one approach over another) 
are presented: 
  Supplemental oxygen is indicated if haemoglobin satura-
tion falls persistently below 90% in previously healthy in-
fants. In this case, adequate supplemental oxygen should be 
used to maintain haemoglobin saturation at or above 90%. 
Oxygen may be discontinued if haemoglobin saturation is at 
or above 90% and the infant is feeding well and has minimal 
respiratory distress. 
  As the child’s clinical course improves, continuous 
measurement of haemoglobin saturation is not routinely 
needed. 
Nasogastric Vs. Intravenous Fluids 
  It is strongly recommended that clinicians should assess 
hydration and ability to take fluids orally [1]. Frequent small 
foods are often used but nasogastric or intravenous fluids 
may be required to maintain hydration. However, fluid re-
placement strategies have not been validated in randomised 
controlled trials (RCTs). A recent study comparing manage-
ment of acute viral bronchiolitis between different centres in 
Australia and New Zealand concluded that practice is 
equally split between nasogastric and intravenous hydration, 
reflecting the current lack of evidence [10]. 
Bronchodilators (Beta 2 Agonists, Epinephrine) 
  As the contribution of airway smooth muscle constriction 
to airway obstruction in most cases is less than the one of 
mucus plugs, cellular debris and mucosal oedema, the ra-
tionale for treatment especially with beta 2 agonists is weak. 
Epinephrine by stimulating the alpha adrenoreceptor also 
causes vasoconstriction in the airway mucosa, and thus may 
result in a decrease of the mucosal oedema. Inhaled bron-
chodilators are widely used in the treatment of infants with 
acute viral bronchiolitis [5]; in emergency departments, es-
pecially nebulised epinephrine is frequently used [11]. Nu-
merous clinical trials and systematic reviews of the literature 
examined the role of bronchodilators in the treatment of 
bronchiolitis. A recent meta-analysis of RCTs comparing 
bronchodilators (other than epinephrine) with placebo in the 
treatment of bronchiolitis including 1428 infants concluded 
that bronchodilators produce small short-term improvements 
in clinical scores but no significant improvement in oxygena-
tion overall or in the rate of hospital admission [12]. Obvi-
ously, results of studies which employed a variety of thera-
pies and outcome measures are difficult to compare, and 
pooling heterogeneous results from a number of studies may 
result in a significant difference of questionable clinical im-
portance. Moreover, the inclusion of studies that enrolled 
infants with recurrent wheezing may have biased the results 
in favour of bronchodilators [12]. Similarly, both a large 
RCT and a Cochrane review concluded that there is insuffi-
cient evidence to support the use of epinephrine in inpatients 
with bronchiolitis [13, 14]; however, there is some evidence 
to suggest that epinephrine may be favourable to salbutamol 
or placebo among outpatients, although admission rates were 
not significantly different [14]. 
  With bronchodilators having no proven effect on the 
course of acute viral bronchiolitis, it is currently recom-
mended that they should not be routinely used in the man-
agement of this disease [1, 3, 5]. A carefully monitored indi-
vidual trial of nebulised alpha-adrenergic or beta-adrenergic 
medication may be justified, but inhaled bronchodilators 
should be discontinued unless a clear positive effect is 
documented [1, 3]. Epinephrine may be the preferred drug 
for such a trial. 
Inhaled Corticosteroids (ICS) 
  In three studies, no effect of ICS was seen on clinical 
scores or length of hospitalisation [15-17]. ICS have also 
been used with the idea to prevent post-bronchiolitic wheez-
ing. A recent systematic review of 5 studies involving 374 
infants did not demonstrate an effect of ICS given during the 
acute phase of bronchiolitis in the prevention of recurrent 
wheezing following bronchiolitis. However, the small num-
ber of included participants and the inability to pool all clini-
cal outcomes precluded the authors from making strong rec-
ommendations [18]. Very recently, another RCT in 243 in-
fants with RSV related lower respiratory tract infection did 
not find an effect of early initiated, prolonged high dose in-
haled corticosteroids on recurrent wheeze [19]. The authors 
thus concluded that the general use of inhaled corticosteroids 
during RSV bronchiolitis should not be advocated. 
Systemic Corticosteroids (Oral, Intramuscular, Intravenous) 
  A meta-analysis performed on 13 RCTs involving 1198 
patients (managed as outpatients or inpatients) found no 
positive effects of systemic corticosteroids on clinical scores, 
hospital admission rates, length of stay or readmission rates 
[20]. More recently, an RCT in previously healthy infants 
hospitalised for acute bronchiolitis (n=174) showed a modest 
benefit of a single intramuscular injection of dexamethasone 
on several outcomes, including length of hospital stay [21]. 
In contrast, a large RCT did not show any effect of a single 
oral dose of dexamethasone in 600 infants presenting with 
moderate-to-severe bronchiolitis at the emergency depart-
ment [22]. Similarly to ICS, oral prednisolone during the 
acute phase of RSV bronchiolitis does not appear to be effec-
tive in preventing post-bronchiolitic wheezing or asthma 
[23]. Based on the data available, the current recommenda-
tion is that systemic corticosteroids should not be used rou-
tinely in the management of acute viral bronchiolitis, irre-
spective of the mode of application or the dose [1]. 
Combination of Epinephrine and Dexamethasone 
  Recently, an RCT involving 800 infants with acute viral 
bronchiolitis who were seen in the emergency department 
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sone, and a combination of both, with hospital admission 
within seven days as the primary outcome [24]. In an unad-
justed analysis, only the infants in the epinephrine-
dexamethasone group were significantly less likely than 
those in the placebo group to be admitted by day 7. After 
adjustment for multiple comparisons, however, the differ-
ence did not reach statistical significance. If confirmed by a 
sufficiently powered study, the suggested moderate effect 
(11 infants would have to be treated to prevent one admis-
sion) due to the frequency of the disease could represent an 
important reduction in the number of hospitalisations. At 
present, however, this combination treatment cannot be rec-
ommended. 
Leukotriene Receptor Antagonists 
  Cysteinyl leukotrienes are significantly increased in res-
piratory secretions from infants with acute viral bronchiolitis 
and remain so at short-term follow-up, suggesting a possible 
role of these substances in the pathogenesis of the disease 
[25]. An RCT compared montelukast, a specific cysteinyl 
leukotriene receptor antagonist, with placebo in infants with 
a first episode of bronchiolitis; treatment was given from 
hospital admission until discharge. Montelukast did not im-
prove length of stay, clinical severity scores or cytokine lev-
els in nasal lavage fluid [26]. Another RCT, serving as a 
pilot study, in 130 infants hospitalised with acute viral bron-
chiolitis showed that a 4-week-course of montelukast re-
duced respiratory symptoms subsequent to RSV bronchiolitis 
[27]. Subsequently, in a larger study infants hospitalised for 
a first or second episode of RSV bronchiolitis (n=979) were 
treated with montelukast for 24 weeks; in this study, monte-
lukast did not improve respiratory symptoms of post-RSV 
bronchiolitis [28]. Similarly, a recent small RCT found that 
treatment with montelukast for three months after hospital 
admission for RSV bronchiolitis did not reduce respiratory 
symptoms during the treatment period and during a 9-month 
follow up period [29]. It follows that montelukast should not 
be used in acute viral bronchiolitis [3]. 
Immunoglobulins and Monoclonal Antibodies 
  A recent Cochrane systematic review assessing immuno-
globulin treatment of RSV infection rather than its role as a 
prophylactic measure identified four RCTs of which none 
demonstrated a statistically significant benefit [30]. 
  Palivizumab, a humanised monoclonal IgG1 antibody 
specifically directed to the RSV fusion protein has been 
shown to be efficacious in preventing serious RSV disease in 
high risk patients [31]. A phase I/II RCT was performed with 
palivizumab in previously healthy children hospitalised with 
acute RSV infection [32]. As this study, showing no signifi-
cant differences in clinical outcomes, was not adequately 
powered, the efficacy of palivizumab as treatment of RSV 
infection remains unclear. The current recommendation is 
that neither immunoglobulins nor RSV monoclonal antibod-
ies should be used in acute viral bronchiolitis [3]. 
Antibiotics 
  Bacteraemia is uncommon in children with RSV infec-
tion, unless they have nosocomial RSV infection, cyanotic 
congenital heart disease, or require intensive care unit admis-
sion [33]. Several RCTs have studied the effect of antibiotics 
on the course of acute viral bronchiolitis. An old study inves-
tigating the effect of ampicillin in an outbreak of bronchioli-
tis reported no positive effect on the disease course [34]. 
This was the only trial that met the inclusion criteria of a 
systematic review on the use of antibiotics in children with 
bronchiolitis [35]. Not surprisingly, this review found no 
evidence to support the use of antibiotics. More recently, the 
authors of a very small study reported that clarithromycin 
was associated with a significant reduction in length of hos-
pital stay and readmission to hospital [36]. In contrast, a 
larger trial in infants hospitalised with RSV bronchiolitis did 
not show a positive effect of azithromycin on duration of 
hospitalisation or resolution of symptoms [37]. The anti-
inflammatory activity of macrolides should be studied in 
larger populations of both outpatients and inpatients. At pre-
sent, it is recommended to limit the use of antibacterial 
medications to children with bronchiolitis who have specific 
indications of the coexistence of a bacterial infection [1, 3]. 
Antiviral Therapy 
  Ribavirin is a broad-spectrum antiviral agent approved 
for treatment of RSV infection, and is the only antiviral drug 
that has been studied in children with acute viral bronchioli-
tis. Its use, however, is controversial because of questions 
about its efficacy, safety concerns, and its high cost. A num-
ber of small studies, lacking sufficient power to provide reli-
able estimates of the effects, have been performed with ri-
bavirin; these have been reviewed recently [38]. Ribavirin 
may reduce the duration of mechanical ventilation and days 
of hospitalisation, and may decrease the incidence of recur-
rent wheezing following bronchiolitis; however, in the ab-
sence of large RCTs, the effect of ribavirin remains un-
proven. Thus, at present ribavirin should not be used rou-
tinely in children with acute viral bronchiolitis [1, 3]. 
Hypertonic Saline 
  Airway oedema and mucus plugging are the predominant  
pathological features in acute viral bronchiolitis. Hypertonic  
saline decreases airway oedema, improves mucus rheologic  
properties and mucociliary clearance, and thus decreases   
airway obstruction [39]. Until 2007, four RCTs on the use of  
aerosolised 3% hypertonic saline solution in children with  
acute viral bronchiolitis were published [40-43]. One study  
was a multi-centre trial [43], the other three were conducted  
by the same group of investigators [40-42]. Outpatients were  
recruited in one trial [40] and inpatients in the other three  
trials [41-43]. Bronchodilators were added to the study   
solution in three studies [40-42]; in the multi-centre study,  
bronchodilators were added in a majority of the treatments  
by attending physicians [43]. A recent systematic review   
which included these four trials, involving 254 infants with  
acute viral bronchiolitis (189 inpatients and 65 outpatients),  
concluded that nebulised 3% saline may significantly reduce  
the length of hospital stay and improve the clinical severity  
score [44]. Recently, another small RCT investigated the use  
of hypertonic saline in the emergency department setting,   
and the authors suggested that immediate clinical benefits   
may not be seen with nebulised hypertonic saline [45]. In  162    The Open Microbiology Journal, 2011, Volume 5  Ernst Eber 
this study, there was a trend towards a reduction in hospitali- 
sation rate with the use of hypertonic saline, but the study  
was not sufficiently powered for this outcome parameter.   
Very recently, an RCT found high volume normal saline to  
be as effective as 3% saline in children with very mild   
bronchiolitis in the emergency department, suggesting that  
the improvement in mucus clearance is not a function of   
the saline concentration but rather of the total mass of   
NaCl added to the airway surface [39, 46]. While there is  
a lack of strong evidence to support the routine use of   
aerosolised hypertonic saline solution in children with   
acute viral bronchiolitis, the lack of side effects and the   
limited cost of the treatment deserve consideration for a   
large RCT. The present recommendation is that hypertonic  
saline should probably be used in the treatment of acute   
viral bronchiolitis [3]. 
Furosemide 
  Inhaled furosemide has been reported to have a positive 
effect in a number of respiratory conditions. It acts only lo-
cally in the lung, but the precise mechanism of action is as 
yet unclear. In a small RCT, safety and the short and long 
term clinical effects of inhaled furosemide were evaluated in 
previously healthy children with acute viral bronchiolitis 
[47]. While inhaled furosemide appeared to be both feasible 
and safe, this pilot study did not show significant clinical 
effects in hospitalised infants with acute viral bronchiolitis. 
Surfactant 
  Clinical and laboratory evidence suggests that severe 
viral bronchiolitis may result in secondary surfactant insuffi-
ciency [48]; thus, exogenous surfactant represents a poten-
tially promising therapy. The efficacy of exogenous surfac-
tant for the treatment of acute viral bronchiolitis in mechani-
cally ventilated infants and children has been assessed in a 
meta-analysis, including three trials with a total of 79 pa-
tients [49]. Use of surfactant was associated with a non-
significant decrease in duration of mechanical ventilation by 
2.6 days and a borderline significant decrease in ICU length 
of stay by 3.3 days. In summary, presently available data on 
surfactant are not sufficient to provide reliable estimates of 
its effects in critically ill children with bronchiolitis. 
Heliox 
  Acute viral bronchiolitis is characterised by airway ob-
struction, resulting in turbulent gas flow. Heliox, a mixture 
of oxygen and the inert gas helium, may improve gas flow 
through high-resistance airways and thus decrease the work 
of breathing. In a very recent meta-analysis, four trials in-
volving 84 infants with RSV bronchiolitis who required pae-
diatric intensive care unit hospitalisation were included [50]. 
The authors of this review concluded that heliox therapy in 
addition to standard medical care for acute viral bronchiolitis 
may significantly reduce respiratory distress in the first hour 
after starting treatment. However, there was no reduction in 
the rate of intubation, in the need for mechanical ventilation, 
or in the length of paediatric intensive care unit stay. Pres-
ently, the place for heliox in the therapeutic schedule for 
severe bronchiolitis is unclear. 
Nasal Continuous Positive Airway Pressure 
  One RCT with a cross-over design compared nasal con-
tinuous positive airway pressure (CPAP) with standard 
treatment consisting of intravenous fluids and supplemental 
oxygen by nasal prongs or face mask in infants with bron-
chiolitis and hypercapnia [51]. When nasal CPAP was used 
first, the reduction in partial pressure of carbon dioxide in 
arterial blood was significantly greater than when CPAP was 
used second. Nasal CPAP was well tolerated with no com-
plications identified. A large trial is needed to investigate 
whether nasal CPAP may reduce the need for invasive venti-
lation. 
Chest Physiotherapy 
  The main goal of chest physiotherapy in paediatric respi-
ratory diseases is to reduce airway resistance and thus the 
work of breathing, and to enhance gas exchange by assisting 
in the clearance of excessive respiratory secretions. A sys-
tematic review performed to determine the efficacy and 
safety of chest physiotherapy in infants with acute bronchio-
litis included three RCTs [52]. The three studies employed 
vibration and percussion techniques with children in postural 
drainage positions compared to no intervention. The authors 
concluded that with the techniques applied, chest physiother-
apy does not reduce length of hospital stay or oxygen re-
quirements, or improve clinical severity scores in infants 
with acute viral bronchiolitis. The current recommendation is 
that chest physiotherapy should not be used routinely in 
children with acute viral bronchiolitis [1, 3]. 
CONCLUSIONS 
  In 1963, Reynolds and Cook stated that “… oxygen is 
vitally important in bronchiolitis and there is little convinc-
ing evidence that any other therapy is consistently or even 
occasionally useful …” [53]. Now, almost fifty years later, 
supportive care including administration of oxygen and flu-
ids still is the cornerstone of treatment of acute viral bron-
chiolitis, and there is no intervention that is of proven benefit 
on the course of the disease or the development of post-
bronchiolitic wheeze. Bronchodilators may be effective in 
some patients and may thus be used on a trial-and-error ba-
sis. Preliminary evidence suggests a potential role for nebu-
lised hypertonic saline, and in infants and children with se-
vere disease the use of nasal CPAP appears to be beneficial. 
Some of the discussed treatments and promising combina-
tions of therapies should be studied in further and larger 
RCTs. 
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